Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

424 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Emerging therapies in non-small-cell lung cancer.
Khuri FR, Herbst RS, Fossella FV. Khuri FR, et al. Among authors: herbst rs. Ann Oncol. 2001 Jun;12(6):739-44. doi: 10.1023/a:1011197500223. Ann Oncol. 2001. PMID: 11484947 Free article. Review.
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin.
Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL. Herbst RS, et al. J Clin Oncol. 2002 Sep 15;20(18):3804-14. doi: 10.1200/JCO.2002.05.102. J Clin Oncol. 2002. PMID: 12228200 Clinical Trial.
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM. Herbst RS, et al. J Clin Oncol. 2002 Sep 15;20(18):3815-25. doi: 10.1200/JCO.2002.03.038. J Clin Oncol. 2002. PMID: 12228201 Clinical Trial.
Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer.
Herbst RS, Madden TL, Tran HT, Blumenschein GR Jr, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA Jr, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T, Hong WK. Herbst RS, et al. J Clin Oncol. 2002 Nov 15;20(22):4440-7. doi: 10.1200/JCO.2002.04.006. J Clin Oncol. 2002. PMID: 12431966 Clinical Trial.
Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study.
Wirth LJ, Lucca J, Ostler P, Fidias P, Lynch C, Jänne PA, Herbst RS, Johnson BE, Sugarbaker DJ, Mathisen DJ, Lukanich JM, Choi NC, Berman SM, Skarin AT. Wirth LJ, et al. Among authors: herbst rs. Clin Cancer Res. 2003 May;9(5):1698-704. Clin Cancer Res. 2003. PMID: 12738723 Clinical Trial.
424 results